869357-63-1Relevant articles and documents
Aryl spiro SHP2 inhibitor compound as well as preparation method and application thereof
-
Paragraph 0135-0137, (2020/10/29)
The invention discloses an aryl spiro SHP2 inhibitor compound as well as a preparation method and application thereof. The invention particularly relates to a nitrogen-containing aryl spiro compound shown as a general formula I (See the specification), or pharmaceutically acceptable salt thereof, or an enantiomer, diastereoisomer, tautomer, solvate, polymorphic substance or prodrug thereof, a preparation method thereof and application thereof in pharmacy, and the definition of each group is shown in the specification.
COMBINATION THERAPY COMPRISING AZD2171 AND AZD6244 OR MEK-INHIBITOR II
-
, (2008/12/08)
The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour, which comprises the administration of AZD2171 in combination with AZD6244 or MEK Inhibitor II; to a pharmaceutical composition comprising AZD2171 and AZD6244 or AZD2171 and MEK Inhibitor II; to a combination product comprising AZD2171 and AZD6244 or AZD2171 and MEK Inhibitor II for use in a method of treatment of a human or animal body by therapy; to a kit comprising AZD2171 and AZD6244 or AZD2171 and MEK Inhibitor II; to the use of AZD2171 and AZD6244 or AZD2171 and MEK Inhibitor II in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation.
HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF
-
Page/Page column 77, (2008/06/13)
Disclosed are MEK inhibitors useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.